Decipher Genomic Classifier Identifies Patients Who Benefit from Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer

/in /by

A major advancement in metastatic hormone-sensitive prostate cancer has emerged from the ENZAMET trial: analysis using the Decipher genomic classifier shows that men with very high-risk tumor profiles benefit significantly from adding docetaxel to standard hormone therapy. Patients with a Decipher score above 0.85 who received the triplet regimen (ADT plus enzalutamide plus docetaxel) had […]

Read more

CRISPR Advances

/in /by

A single infusion of a CRISPR-based therapy has significantly reduced attacks in patients with hereditary angioedema (HAE) in what appears to be the first successful Phase III trial of an in vivo gene-editing treatment. The findings, presented at a major European congress and published in the New England Journal of Medicine, mark a turning point […]

Read more

Turning Prostate Cancer from Cold to Hot: How Tiny Silica Particles Kill Tumors and Wake Up the Immune System

/in , /by

For years, advanced prostate cancer has been the textbook example of an “immunologically cold” tumor: it doesn’t provoke a strong immune response, carries few mutations that help the immune system recognize cancer, and is packed with cells that actively suppress immunity. Because of this, immune checkpoint inhibitors have largely failed in this disease. Against this […]

Read more

Killing the Last 0.1%: Targeting Cancer Persister Cells

/in /by

Cancer therapy has a persistent blind spot. Tumors shrink, biomarkers improve, scans look clean—and yet relapse remains common. The reason is often a tiny population of surviving cells known as persisters. These cells are not genetically resistant. They are identical to the bulk tumor but enter a transient, drug-tolerant state that allows them to survive […]

Read more

Phase III PrTK03 Trial Results: Aglatimagene Besadenovec (CAN-2409) Improves Survival in Localized Prostate Cancer

/in , /by

The phase III PrTK03 trial, reported in The Lancet Oncology, demonstrates that adding aglatimagene besadenovec (CAN-2409) plus valacyclovir to standard radiotherapy improves disease-free survival in patients with localized prostate cancer. Aglatimagene is an intratumoral adenoviral gene therapy that delivers the HSV-tk gene, enabling tumor cells to convert the prodrug valacyclovir into a cytotoxic metabolite that […]

Read more

Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer

/in , , /by

61Cu-NU101 is a new PSMA-targeted PET/SPECT tracer for prostate cancer that showed promise in phase 1, detecting more lesions than 18F-piflufolastat (Pylarify) in half of the 8 patients studied, with lower background uptake and no side effects. The key advantage is its 3.3-hour half-life, compared to 68 minutes for 68Ga-PSMA-11 and 109 minutes for 18F-piflufolastat. […]

Read more

UPDATE: Memantine for Neuroendocrine Prostate Cancer, Early Efficacy Signals

/in , , /by

Prostate cancer can become harder to treat when it changes from the usual adenocarcinoma form into neuroendocrine prostate cancer, or NEPC. A recent study suggests that this transition may begin earlier than expected, during an intermediate phase when the cells are still partly prostate-like but are already starting to acquire neuroendocrine features. A central finding […]

Read more

BRCA-Altered mCSPC Progresses Faster on ARPIs: A Real-World Treatment Gap

/in , /by

Recent real-world data clarify how homologous recombination repair (HRR) alterations, especially BRCA1/2 mutations, affect outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with androgen receptor pathway inhibitors (ARPIs). In a US cohort of 745 patients, overall differences in time-to-next-treatment (TTNT) and time-to-castration resistance (TTCR) were modest between patients without HRR alterations and those with non-BRCA […]

Read more